Drug Profile
Research programme: antibody-drug conjugates - Mersana Therapeutics/Takeda Oncology
Alternative Names: Fleximer® antibody-drug conjugate - Mersana Therapeutics/Takeda OncologyLatest Information Update: 28 Feb 2019
Price :
$50
*
At a glance
- Originator Mersana Therapeutics; Millennium
- Developer Mersana Therapeutics; Takeda Oncology
- Class Antibodies; Drug conjugates; Immunoconjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Feb 2019 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 14 May 2018 Mersana Therapeutics has patent protection in USA and foreign countries across its platforms and programmes
- 14 May 2018 Mersana Therapeutics has patent protection for its Fleximer polymer-based Dolaflexin platform in USA